Skip to main content
Premium Trial:

Request an Annual Quote

Applied Precision, PriTest, The Commissariat a l Energie Atomique and Universite Joseph Fourier de Grenoble, and Fujitsu of Kawasaki

Premium

Applied Precision of Issaquah, Wash., has received US Patent No. 6,862,363, “Image metrics in the statistical analysis of DNA microarray data.” The patent covers probability density distributions generated by pixel-by-pixel analysis of microarray images that can be used to measure the precision with which spot intensities are determined. Simple weighting schemes based on these probability distributions are effective in improving significantly the quality of microarray data as it accumulates in a multi-experiment database, according to the patent, and error estimates from image-based metrics should be one component in an 6342355 probabilistic scheme for the analysis of DNA microarray data.


PriTest of Redmond, Wash., has received US Patent No. 6,861,251, “Translucent solid matrix assay device for microarray analysis.” The invention concerns methods and compositions for matrix arrays. In preferred embodiments, the arrays are translucent and reconfigurable. Reconfigurable arrays may be produced using small linker molecules, such as aptamers or affibodies, attached to the array substrate. Preferably, the small linker molecules bind to an IgG-specific portion of antibodies. Such arrays may be used to detect any target that binds selectively or specifically to an IgG, allowing flexibility of use. Translucent matrix arrays may use a translucent, colloidal form of nitrocellulose to coat the array substrate.


The Commissariat a l’Energie Atomique and Universite Joseph Fourier de Grenoble, both of France, have received US Patent No. 6,861,515, “Analysis of biological targets using a biochip comprising a fluorescent marker.” This invention covers an analytical support bearing several oligonucleotides, where each of the nucleotides is marked by a fluorescent compound that changes in fluorescence on the hybridization of the oligonucleotide with a complementary oligonucleotide. This makes it possible to perform an analysis of biological targets by measuring fluorescence to determine the hybridization of the targets with the oligonucleotides of the support.


Fujitsu of Kawasaki, Japan, has received US Patent No. 6,861,224, “Protein detecting device.” The invention relates to a device for detecting or determining proteins without labeling them. The device comprises a detecting unit with a bonding section, a detecting section, and an electrode section detecting the change in electrical conductivity in the polynucleotide double strand. It is also an object of the invention to provide a technique, which serves as a constituent technique applicable to a so-called array-chip technology, for obtaining data useful in proteomics.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.